Balaxi Pharmaceuticals Ltd

Balaxi Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Balaxi Pharmaceuticals Ltd

₹ 83.4 -0.87%
12 Dec 11:34 a.m.
balaxiventures.in NSE: BALAXI
About

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]

Key Points

Product Portfolio
Balaxi Pharmaceuticals Limited has a rich portfolio of 610 pharmaceutical product registrations. The pharma product portfolio of the company includes Tablets (46%), Injectables(17%), Liquids (12%), Capsules (13%), and Others (12%). The pharma products are sourced from WHO-GMP certified contract manufacturers based in India, China, and Portugal. [1] [2] [3]

Website NSE
  • Market Cap ₹ 461 Cr.
  • Current Price ₹ 83.4
  • High / Low ₹ 151 / 74.0
  • Stock P/E 14.0
  • Book Value ₹ 39.1
  • Dividend Yield 0.00 %
  • ROCE 20.7 %
  • ROE -25.9 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Company has a low return on equity of 10.2% over last 3 years.
  • Debtor days have increased from 59.0 to 84.3 days.
  • Promoter holding has decreased over last 3 years: -6.87%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
70.23 61.72 89.10 82.78 86.38 86.58 80.68 65.96 54.72 60.79 59.83 65.62 77.38
56.20 48.16 77.88 69.02 71.63 71.29 67.93 57.12 43.96 47.14 46.36 55.53 66.79
Operating Profit 14.03 13.56 11.22 13.76 14.75 15.29 12.75 8.84 10.76 13.65 13.47 10.09 10.59
OPM % 19.98% 21.97% 12.59% 16.62% 17.08% 17.66% 15.80% 13.40% 19.66% 22.45% 22.51% 15.38% 13.69%
0.13 -0.40 4.07 3.28 4.14 -4.57 -0.22 -47.68 5.93 1.51 -0.70 -1.85 -4.11
Interest 0.01 0.02 0.10 0.20 0.02 0.01 0.27 0.29 0.37 0.41 0.61 0.37 0.45
Depreciation 0.12 0.16 0.17 0.19 0.19 0.19 1.19 0.29 0.66 0.48 0.67 0.49 0.46
Profit before tax 14.03 12.98 15.02 16.65 18.68 10.52 11.07 -39.42 15.66 14.27 11.49 7.38 5.57
Tax % 14.11% 6.16% 15.38% 15.08% 17.08% 21.86% 26.83% 4.90% 7.92% 4.77% 4.87% 12.06% 17.41%
12.05 12.18 12.71 14.15 15.49 8.23 8.10 -41.34 14.43 13.59 10.93 6.48 4.59
EPS in Rs 2.41 2.44 2.54 2.83 3.10 1.64 1.59 -8.07 2.82 2.65 2.01 1.17 0.83
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
14 46 231 279 336 241 264
12 37 189 229 279 197 216
Operating Profit 2 8 43 51 57 45 48
OPM % 11% 18% 18% 18% 17% 18% 18%
1 1 2 5 3 -38 -5
Interest 0 0 0 1 1 3 2
Depreciation 0 0 0 1 2 2 2
Profit before tax 2 9 44 55 57 2 39
Tax % 19% 31% 14% 13% 19% 219%
2 6 38 48 46 -2 36
EPS in Rs 1.30 1.22 7.63 9.53 9.03 -0.44 6.66
Dividend Payout % 0% 0% 0% 1% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 78%
3 Years: 1%
TTM: -8%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 14%
Stock Price CAGR
10 Years: %
5 Years: 42%
3 Years: -7%
1 Year: 0%
Return on Equity
10 Years: %
5 Years: 18%
3 Years: 10%
Last Year: -26%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 3 10 10 10 10 11 11
Reserves 0 18 55 103 173 190 205
0 0 4 4 13 19 32
3 8 31 60 43 38 40
Total Liabilities 6 36 100 176 240 258 288
0 0 2 29 41 41 43
CWIP 0 0 0 1 3 2 0
Investments 0 0 3 0 0 0 0
6 36 94 147 195 215 245
Total Assets 6 36 100 176 240 258 288

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-2 -14 0 34 6 5
-0 -0 -6 -28 -11 -1
0 18 4 -0 26 30
Net Cash Flow -2 4 -2 6 21 34

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 147 238 121 36 57 84
Inventory Days 9 29 184 189 233
Days Payable 64 53 92 62 82
Cash Conversion Cycle 147 183 97 129 184 235
Working Capital Days 82 181 96 97 133 168
ROCE % 57% 93% 60% 37% 21%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
72.86% 72.86% 72.86% 72.86% 72.69% 71.57% 71.22% 71.22% 71.22% 66.86% 65.99% 65.99%
0.00% 0.00% 0.00% 19.00% 18.95% 18.66% 18.57% 18.57% 18.57% 17.21% 16.88% 16.48%
19.48% 19.31% 19.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.02% 0.02% 0.02%
7.64% 7.83% 8.11% 8.11% 8.33% 9.75% 10.18% 10.18% 10.18% 15.91% 17.11% 17.50%
No. of Shareholders 3,8713,9884,1764,8004,7304,8595,1235,0475,0455,2066,5867,863

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls